Results consistent with previous trials, reinforcing benefit of Daiichi Sankyo and AstraZeneca’s ENHERTU in previously treated patients
New deal strengthens Congenica’s presence in India
Pharmaceutical sales de-grew 18% YoY and stood at Rs. 224 crore whereas Crop Protection sales de-grew by 15% at Rs. 154 crore
EBITDA stood at Rs. 39.9 crore and EBITDA margin for the quarter was 38.2% whereas Profit After Tax (PAT) stood at Rs. 17.5 crore translating into a PAT margin of 16.7%
Profit after Tax stood at Rs. 105 crore as compared to Rs. 119 crore on account of higher treasury income in Q1 FY22, non-cash ESOP cost, depreciation on account of acquired brands and finance costs in Q1 FY23
Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
Driven by a strong commitment to better serve its global customers in medical and consumer products, this investment represents the largest capacity expansion in Cariflex’s existing accomplishments
The region's digital health market, valued at USD 40.3 billion in 2021, is expected to expand to USD 326.7 billion by 2030 at a CAGR of 26.5 per cent.
Subscribe To Our Newsletter & Stay Updated
